RESULTS:
Ninety-nine patients (ages 1.3-25.7 years) and 102 apheresis events were available for analysis. Patients underwent apheresis at a variety of absolute lymphocyte cell counts, with a median absolute lymphocyte count of 944 cells/lL (range, 142-6944 cells/lL). Twenty-two patients (21.6%) had absolute lymphocyte counts less than 500 cells/lL. The mononuclear cell target was obtained in 100% of all apheresis harvests, and chimeric antigen receptor T-cell production was possible from the majority of collections (94%). Mononuclear cell collection efficiency was 65.4%, and T-lymphocyte collection efficiency was 83.4%. Ten patients (9.8%) presented with minor adverse events during the 102 apheresis procedures, with one exception of a severe allergy.
CONCLUSIONS:
Mononuclear cell apheresis for chimeric antigen receptor T-cell therapy is well tolerated and safe, and it is possible to obtain an adequate quantity of CD31 lymphocytes for chimeric antigen receptor T-cell manufacturing in heavily pretreated patients who have low lymphocyte counts.
A doptive cellular therapy has emerged as a pivotal opportunity to improve outcomes for patients with cancer. 1, 2 The antigen specificity of T cells can be manipulated by genetic modification and redirected to successfully target antigens that are expressed by tumors. 3 Autologous T cells engineered to express a chimeric antigen receptor (CAR) are a powerful targeted immunotherapy. 4 These approaches overcome the fundamental limitations associated with central and peripheral immune tolerance, and they generate T cells that are more efficient in targeting tumors without the requirement for de novo T-cell activation in the patient.
Early phase clinical trials using CAR T cells targeting CD19 have resulted in complete response (CR) rates as high as 93% in patients with relapsed and refractory precursor B-cell acute lymphoblastic leukemia (ALL), [5] [6] [7] and the same methods are being applied to target tumor antigens expressed on solid tumors. [8] [9] [10] [11] The production of CAR T cells involves the collection of autologous, patientderived T cells that are genetically modified ex vivo by viral transduction to express an antigen-recognition domain attached to intracellular signaling domains, which mediate T-cell activation in a major histocompatibility complex-independent manner, and the subsequent expansion of these modified T cells in culture. 7 A major barrier to the overall success of the therapy in some studies has been the exclusion of research participants based on failure to manufacture a viable CAR T-cell product.
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The first essential step in the production of CAR T cells is the safe and effective apheresis of autologous T cells from a patient. Although it has been demonstrated that collection of the mononuclear cell (MNC) layer is a safe and efficient method for collecting T cells necessary to produce CAR T-cell products, the optimal apheresis collection parameters have yet to be established, particularly in pediatric patients at the low end of the weight spectrum. 13 Protocols for CD341 peripheral blood (PB) stem cell harvest for hematopoietic stem cell transplantation (HSCT) are well established, as are protocols for leukapheresis in hyperleukocytic leukemia. In both of these settings, the total white blood cell (WBC) count typically is elevated due to medication or the disease process itself, and the target cells for collection are larger, immature lymphocytes. Therefore, the principles in these apheresis protocols are not easily transferrable to T-cell collection for CAR T-cell manufacturing, when patients often have low total WBC counts, and the target cells for collection are mature lymphocytes, which are smaller and more dense, potentially making apheresis more of a technical challenge because of the difficulty in establishing the red blood cell-WBC interface in the centrifuge. 13 The most similar procedure is the apheresis collection for donor lymphocyte infusion, because, in both procedures, mature T cells are the target cells. However, lymphocyte infusion donors are healthy volunteers with normal WBC counts, whereas patients undergoing collection for CAR T-cell manufacturing often have low absolute lymphocyte counts (ALCs) and have been heavily previously treated with chemotherapy, HSCT, and/or radiation. In the setting of hematologic malignancies, patients may have large numbers of circulating blasts. Given the rapidly increasing number of clinical trials utilizing adoptive cellular therapies and the efficacy of this therapy demonstrated to date, defining a simple and effective protocol for T-cell collection is essential. We previously reported a robust intent-to-treat product-manufacturing success rate of 100% in minimally selected, heavily pretreated patients with ALL in our Pediatric and Young Adult Leukemia Adoptive Therapy (PLAT)-02 study (clinicaltrials.gov identifier NCT02028455). 7 There are only two reports of lymphocyte apheresis in a heavily pretreated population with leukemia or neuroblastoma.
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Here, we report our experience in T-cell collection via apheresis for CAR T-cell manufacturing in pediatric and young adult patients with relapsed and refractory leukemia, lymphoma, and neuroblastoma.
MATERIALS AND METHODS

Patients
The Apheresis was performed on an apheresis COBE Spectra machine (Terumo BCT) using the MNC collection program. The procedure parameters, which were developed by our program, include an initial blood volume calculation to determine whether the patient requires a blood prime. The anticoagulant (acid citrate dextrose solution A [ACDA]) ratio to blood was 12:1 if the patient weighed greater than 44 kg. If the patient weighed 44 kg or less, then 10,000 units of unfractionated heparin were added to the 1000-mL ACDA bag, increasing the ratio to 22:1. The COBE Spectra machine was primed with unheparinized ACDA, and heparin was used only after the prime was complete. Patients who weighed less than 25 kg or those who had a calculated percentage of extracorporeal volume greater than 12% required blood priming of the apheresis circuit. If there was a clinical concern about the fluid shifts during the procedure, then the medical oversight physician determined the requirement for a blood prime on a case-by-case basis. The collect pump rate was set at 1.0 mL/min, and the maximum inlet rate was set at 100 mL/min. The product target volume was set to be no more than 600 mL, including the MNC product, autologous concurrent plasma, and anticoagulant. An additional 20 mL of ACDA was added aseptically to the product. Autologous concurrent plasma was added to the PLAT-02 collections, but not to the ENCIT-01 collections, to standardize the volumes received by the cell-processing facility. The collection line was kept at 2% to 3% based on a WBC colorgram provided by the manufacturer. To prevent hypocalcemia, intravenous calcium gluconate was administered at a rate and dose of 50 mg/kg/hr. The patients had ionized calcium levels checked on a pointof-care device at the bedside before the procedure, every 30 minutes during the procedure, and at the end of the procedure. Those who had ionized calcium levels less than 1.0 mg/dL were treated with a 20 mg/kg calcium gluconate bolus or a slowing of the rate of the collection, depending on the medical provider's assessment. If the ionized calcium was greater than 1.4 mg/dL, then the calcium infusion was paused, and the level was checked again 10 to 15 minutes later before re-starting the infusion. Patients underwent the apheresis procedure with a collection target of 1 3 10 9 total MNCs/kg and a predicted efficacy of 40% (see below). The following algorithm was used to determine the target total blood volume (TBV) to be processed, with a minimum of 3 TBVs or 9 L (whichever is less): 1 3 10 9 /(total MNCs/mL 3 TBV [weight in kg 3 70 mL] 3 0.4).
To monitor collection efficiency and patient status, a complete blood count with automated and manual differential was performed before and after each apheresis procedure. A total WBC count with differential also was performed on the apheresis product after harvest to measure total MNCs and the total lymphocyte count (TLC). Lymphocyte phenotype was determined by flow cytometry of the PB before apheresis (data available for 97 MNC apheresis procedures) and in the apheresis products. These data were used for research studies only and were not used to define the apheresis blood volume processed.
Adverse events occurring during the procedures were collected by chart review. The hematocrit and platelet values before and after the procedures were collected to evaluate whether the apheresis procedure caused a significant change in these laboratory values.
Statistical analysis
The collection efficiency for MNCs and T lymphocytes was calculated as follows: MNCs recovered/MNCs expected (preapheresis PB MNCs 3 mL blood processed 3 1000) and T lymphocytes recovered (percentage CD31 3 total MNCs recovered)/MNC expected (preapheresis PB ALC 3 mL blood processed 3 1000), respectively. Median and range (minimum/maximum) values or frequencies and percentages were collected for all study variables. Differences between variables were analyzed by the independent t test for normally distributed variables and the Mann-Whitney test for non-normally distributed variables. A two-tailed p value less than 0.05 was considered significant.
RESULTS
Eighty patients from PLAT-02 and 19 from ENCIT-01 were included in this analysis. Three patients enrolled on PLAT-02 underwent a second apheresis: two because their first T-cell product generation was unsuccessful, and one because of a positive blood culture at the time of apheresis. Therefore, in total, 102 apheresis events were available for analysis.
Patients enrolled on the ENCIT-01 study were younger compared with those enrolled on the PLAT-02 study, and the median patient age at the time of apheresis was 7.2 and 12.6 years, respectively (p 5 0.13). The median age of patients at the time of apheresis was 11.6 years (range, 1.3-25.7 years), and the median weight at the time of apheresis was 34.7 kg (range, 10-127.8 kg; 58.6% of patients weighed less than 40 kg) ( Table 1 ). Patients began their apheresis procedure at a variety of WBC counts and ALC levels, with a median WBC count of 5000 cells/lL (range, 600-85,300 cells/lL) and a median ALC of 944/lL (range, 142-6944 cells/lL) ( Table 2) . Twenty-two patients (21.6%) had a total ALC less than 500 cells/lL at the time of apheresis. In addition, the median PB CD31 lymphocyte count/lL was 580 (range, 3-2623 cells/lL). Twentyfour patients (24.7%) and 45 patients (46.4%) had less than 150 and 500 CD31 cells/lL in the PB, respectively.
The median total MNC count (calculated as MNCs * estimated TBV in liters) in the PB before apheresis was 4.29 3 10 9 (range, 0.4 3 10 9 to 7.55 3 10
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). For those enrolled on PLAT-02, 28 of 83 patients (33.7%) had circulating blasts at the time of apheresis, with a median percentage of blasts of 38% (range, 1%-98%), and a median total blast count of 1780 blasts/lL (range, 54-81,888 blasts/lL).
Of the 102 collection procedures, the median volume of blood processed was 8001 mL (range, 2760-13,294 mL) for the total cohort and 6274 mL (range, 3081-12,001 mL) for patients enrolled in ENCIT-01. The median calculated TBV processed was 3.4 L (range, 0.9-6.4 L). The target MNC count (>1 3 10 9 cells) was obtained in 100% of all apheresis harvests. The apheresis collection yields demonstrated a median total MNC count of 8.8 3 10 9 (range, 1.2 3 10 9 to 2.98 3 10
) and a median TLC of 3.2 3 10 9 (range, 0.3 3 10 9 to 6.22 3 10 10 ) ( Table 2 ). The MNC and T-lymphocyte collection efficiencies were 65.4% (range, 17.7%-2240%) and 83.4% (range, 13.7%-6103.2%), respectively.
Most collections resulted in sufficient numbers of viable T lymphocytes for the production of a CAR T-cell . † t tests were used to determine these p values; others were determined with the Mann-Whitney test. ‡ MNC recovered/MNC expected (preapheresis blood MNC*mL blood processed*1000). § Lymphocytes recovered/expected (preapheresis ALC*mL blood processed*1000). ABC 5 absolute blast count; AMC 5 absolute monocyte count; TMNC, total mononuclear cells.
product. However, in 6 of 102 apheresis collections (5.9%), CAR T-cell manufacturing was not possible. Three of these patients were enrolled in the PLAT-02 study and underwent a second apheresis collection: One underwent a second apheresis because of concerns about product contamination when the patient had a positive blood culture result after collection; and two patients underwent a second apheresis because, despite adequate starting material, there was insufficient cell growth in the laboratory. CAR T-cell manufacturing was possible for all of these three patients after the second collection. Finally, in one patient with leukemia in the PLAT-02 study, CAR Tcell manufacturing was aborted when the patient died 10 days after apheresis. In two patients who had relapsed/ refractory neuroblastoma on the ENCIT-01 study, CAR Tcell manufacturing was not possible due to insufficient cell growth of the CD8 product in the laboratory. Both patients had recently undergone metaiodobenzylguanidine (MIBG) therapy within 8 weeks of apheresis. A second collection was not performed in either patient, and the protocol was amended to require that patients who had undergone MIBG therapy had at least a 12-week wash-out period before undergoing apheresis. In the four total apheresis products that had insufficient cell growth in the laboratory (two products from patients with leukemia and two from patients with neuroblastoma), the median MNC count in the apheresis product was 9.1 3 10
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, which was greater than the median MNC count for the entire patient cohort, and the median calculated CD31 cell count was 1.84 3 10 9 cells/lL, which was slightly lower than the median CD31 count for the entire cohort. In the two patients with leukemia on the PLAT-02 study who had poor cell growth, no blasts were present in the PB before apheresis. No determination was evident from the starting material to explain the lack of sufficient cell growth. Overall, the apheresis procedure was well tolerated by patients. No patients had bleeding or symptoms of hypocalcemia during the 102 apheresis sessions. In eight apheresis sessions, an unstable interface was noted by the apheresis nurse, but these products resulted in appropriate collections, and CAR T-cell product manufacturing was not impacted. Only 10 reactions were reported over 102 apheresis procedures (9.8%). Nine patients experienced minor complications, including hypotension requiring a bolus (n 5 4; 3.9%), fever (n 5 2; 1.8%), pain (n 5 2; 1.8%), and agitation (n 5 1; 0.9%) ( Table 3) . Only one reaction was considered severe, in which a patient developed itchy eyes, itchy throat, and sneezing (Common Terminology Criteria for Adverse Events Grade 2 allergic reaction) during the apheresis procedure; specifically, this occurred when the tubing was initially connected from the instrument to the patient's circulation. The onset of symptoms was attributed to the coating of the tubing. After changing the tubing and performing a double-prime rinse of the circuit, the apheresis procedure was tolerated without further complication. Laboratory values were assessed before and after apheresis. The median decrease in hematocrit and platelet counts after apheresis were 1.8% (range, 24.2% to 8.7%) and 40.5 K/mm 3 (range, 214 to 922 K), respectively (Table   4) . One patient had a very high platelet count before apheresis (1103 K), followed by a dramatic drop in the platelet count after apheresis (the decrease in platelet count was 922 K), resulting in a wide range in the fall of platelet counts. The median low and peak ionized calcium levels were 1.16 mmol/L (range, 0.7-1.36 mmol/L) and 1.36 mmol/L (range, 1.16-1.54 mmol/L), respectively (Table 4) . Five patients (6%) received a calcium bolus for an ionized calcium level below 1.0 mmol/L during the procedure.
DISCUSSION
We report here the largest series of T-cell collection by apheresis, including 99 children and young adults who underwent CAR T-cell therapy for refractory ALL, nonHodgkin's lymphoma, and neuroblastoma at Seattle Children's Hospital. Apheresis for T-cell collection is the first step in the complex manufacturing process of therapeutic CAR T cells, and a successful collection is necessary for the rest of the manufacturing process to proceed. Our study included pediatric and young adult patients who had two categories of diagnosis: leukemia/lymphoma or neuroblastoma. Although the patients were enrolled on two separate trials (PLAT-02 and ENCIT-01) with different treatment approaches appropriate for each disease, the approach to apheresis collection was the same on both trials, and there were no significant differences in apheresis collection yield parameters. Although most patients were heavily pretreated and had low ALC counts at the time of apheresis, the targeted MNC count (>1 3 10 9 cells/kg) was obtained in 100% of all apheresis harvests. CAR T-cell manufacturing was successful after 96% of these collections. Because of the pathogenesis of the disease, patients with neuroblastoma were younger and had lower body weights; therefore, a blood prime was performed in most patients (17 of 19) enrolled on ENCIT-01. In addition, the median total MNC count in the PB before apheresis in PLAT-02 patients was higher (p 5 0.045), probably because several patients had high blast counts before collection. There was no difference in the PB ALC between patients with neuroblastoma and those with leukemia.
Complications occurred in only 9.8% of the apheresis sessions. All complications were easily managed, and in only one patient (0.98%) were the symptoms moderate to severe. Although there was a statistically significant decrease in the median hematocrit and platelet counts after the collection procedure, most patients did not meet criteria for red blood cell or platelet transfusion. Our results confirm that apheresis procedures are relatively safe, as reported by Yuan and colleagues in a recent retrospective analysis of 15,763 procedures. 18 That group reported only 59 (0.37%) moderate-to-severe adverse events, including dizziness or fainting episodes (0.12%), citrate toxicity (0.02%), a combination of dizziness/fainting and citrate toxicity (0.11%), vascular injuries (0.07%), and miscellaneous events (0.04%).
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Our study has some limitations. For instance, it is impossible to define possible risk factors for CAR T-cell product growth failure related to apheresis characteristics from our available data. However, in the case of the two patients with neuroblastoma who did not have adequate cell growth, both patients had received I-131-MIBG therapy only 8 weeks before the attempted harvest. After the second case of poor cell growth in this setting, the protocol was modified to require that patients who had undergone MIBG therapy had at least a 12-week lag period before undergoing apheresis.
Allen and coworkers reported 71 CD31 cell collections from patients participating in three CAR T-cell National Institutes of Health clinical trials. 14 In their study, those authors used the preapheresis CD31 cell count to extrapolate the number of liters to be processed. In the CTL019 trials, a minimum ALC of 500 cells/mL is required; or, if the ALC is below 500/lL, then the absolute CD31 lymphocyte count must be greater than 150 cells/lL. 15 In our study, a minimum ALC count of only 100 cells/mL, with a target collection of 1 3 10 9 MNCs, was needed to have an adequate apheresis product for manufacturing CAR T cells. Considering that almost 25% of the patients had less than 150 CD31 cells/lL in the PB before apheresis, our results demonstrate the feasibility of manufacturing CAR T cells in patients with very low CD31 cell counts. Because CAR T cells soon may be available on a broader scale, our straightforward operating procedure would be easy to adopt at regional apheresis sites. As the planned volume for collection is based on the total MNC count and is not specific to the total number of CD31 cells, our method may underestimate or overestimate the efficacy of T-lymphocyte collection because of either very high or very low CD31 cells counts in the PB before apheresis. This is demonstrated by our range of efficacy of T-cell recovery, which was between 3% and 2623% in our cohort. As apheresis technology advances, so does our approach. Although it was not included in this study, we have progressed to using the Spectra Optia device (Terumo BCT). Using the continuous MNC collection program, we have adopted many of the same parameters used with the COBE Spectra, as described above, although we have decreased the approach to anticoagulation for patients who weigh less than 44 kg. Specifically, for these lowweight patients, we decreased the heparin dose by half (to 5000 units in 1000 mL ACDA bags). The Spectra Optia machine is primed with unheparinized ACDA, and the heparin is used only after the prime is complete. The collection starts with an ACDA ratio of 15:1 for the first 200 to 500 mL of inlet volume, while the operator monitors for clumping. If there is no clumping, then the ACDA ratio can be changed to 18:1, and a second 200 to 500 mL of inlet volume is processed while clumping monitoring continues. The target ACDA ratio is 22:1.
In conclusion, MNC apheresis for CAR T-cell therapy is well tolerated and safe, and it is possible to obtain a sufficient quantity of CD31 lymphocytes for manufacturing in heavily pretreated pediatric and young adult patients who have low ALCs.
